ArticleInfectious agents and cancer2026
Interoperability of two commercial kits in detecting high oncogenic human papilloma virus and genetic diversity in Cameroon: implications for cervical cancer screening strategies in resource-limited settings.
Article in Infectious agents and cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCameroon lacks a national screening algorithm for Human papilloma virus (HPV) infection. In order to standardize HPV screening using molecular detection tools in Cameroon, this study aimed to evaluate the concordance of HPV detection via two multiplex systems and profile the epidemiology of High-risk oncogenic HPV (HR-HPV) circulating locally.
methodsA cross-sectional study was conducted on endocervical samples collected among women in Cameroon. HR-HPV detection and genotyping was done using Abbott and Sacace kits simultaneously. Discordant results were retested using Anyplex II HPV28 kit.
resultsOf 364 participants enrolled (median-age: 42 [IQR:34-50] years), overall HR-HPV positivity was 21.4% (78/364) versus 15.4% (56/364) using Abbott and Sacace, respectively. Detection concordance between the test kits was strong (kappa-value = 0.8). Of 22 samples with discordant results, 86.36% (19/22) were further confirmed with Anyplex II HPV28; yielding an overall HR-HPV positivity prevalence of 20.6% (75/364), with 12 genotypes circulating. The most prevalent genotypes were HR-HPV_16 (18.8%), HR-HPV_18 (16.0%), HR-HPV_39 (16.0%), and HR-HPV_58 (13.0%). Discrepancy in the detection of different and/or same genotype was more prominent for HPV 18 (6/9). Though Sacace is suitable to further discriminate among genotypes, cost-analysis showed that Abbott was 50.6% cheaper in reagents per test.
conclusionsThis study revealed a strong concordance between Abbott and Sacace kits for HR-HPV detection, demonstrating interoperability of these two multiplex systems available locally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.